Analysis
Forus raised new funding, Bloomberg reported, roughly tripling the company's valuation in about four months since the company was founded in 2023. The round:
- Series C: $150M, led by Bain Capital Ventures
- New valuation: $3B, up from Forus's Series B mark in May 2026
- Also participating: Thrive Capital, General Catalyst, Accel, Redpoint Ventures, BoxGroup, Pear VC, Vast Ventures and SV Angel, several returning from the $160M Series B
- Total funding to date: more than $300M
Forus uses AI to automate the steps between a doctor writing a prescription and a patient actually getting the drug: checking insurance coverage, applying manufacturer financial-assistance programs, and navigating pharmacy logistics. That workflow -- often called prior authorization and prescription access -- has historically run through fax machines, phone trees and manual pharmacy-benefit-manager portals, and is widely blamed for patients abandoning prescriptions they can't afford or can't get approved in time.
The competitive field
Forus is going after CoverMyMeds, the McKesson-owned incumbent that has run prior-authorization workflows for pharmacies and providers for over a decade and processes requests for the large majority of US pharmacies. It also sits adjacent to consumer-facing drug-pricing tools like GoodRx, though Forus's product is aimed at the provider and payer side of the transaction rather than direct-to-consumer pricing. The pitch to investors is that an AI system built from scratch in 2023 can move faster and integrate more automation into a workflow CoverMyMeds has largely run as a static portal.
A 3x markup in four months is aggressive even by 2026's AI-funding standards, and it puts real pressure on Forus to show revenue growth that justifies the pace -- neither Bloomberg's report nor the company disclosed current ARR or customer count alongside the round.
The counterweight
Prior authorization is also one of the most politically charged corners of US healthcare right now, with state legislatures and CMS both pushing reforms to speed up or eliminate manual review steps. A regulatory change that simplifies or removes prior authorization requirements outright would cut directly into the workflow Forus is automating -- a policy risk that doesn't show up in a valuation multiple.
What to watch
Whether Forus discloses revenue or retention metrics at its next round will say more about whether this valuation holds than any investor name on the cap table.
